Breaking the Solid Tumor Barrier: We've Proven It Can Work—Now What?

Session details:

With recent clinical successes demonstrating that CAR-T and TCR-T therapies can generate meaningful responses, the question is no longer whether cell therapy can work in solid tumors, but how to expand its impact through better engineering, combination strategies, and patient selection. Discussion Points

• What lessons have emerged from the first clinical successes in solid tumors?
• Which biological barriers—including the tumor microenvironment, trafficking, persistence, and antigen heterogeneity—remain the most difficult to overcome?
• Where are CAR-Ts and TCR-Ts each best positioned to succeed?
• How should engineered cell therapies be combined with other treatment modalities—including checkpoint inhibitors, T-cell engagers, cytokines, or other immune-modulating agents—to improve outcomes?
• Which tumor types and patient populations are poised to benefit next?